For premenopausal patients with ER+ PR+ HER2 negative breast cancer and lymph node micrometastases, would recurrence score be most appropriately interpreted based on TAILORx data, given such patients were excluded from RxPONDER?
Answer from: Medical Oncologist at Academic Institution
These patients were excluded from TAILORx. Patients with micrometastases were initially allowed in RxPONDER but then excluded after the first ~2500 patients had been enrolled (presumably because too many patients with micromets were being enrolled and the study team wanted to ensure results would be...
Comments
Medical Oncologist at Warren Alpert Medical School of Brown University I agree but would take the volume of nodal involve...
Medical Oncologist at Ascension Michigan St. John Hospital Would you tend to avoid it if pN1mic then? That&rs...
Medical Oncologist at Wisconsin Oncology Per RxPONDER data, premenopausal patients with eve...
I agree but would take the volume of nodal involve...
Would you tend to avoid it if pN1mic then? That&rs...
Per RxPONDER data, premenopausal patients with eve...